Search Results
Oct 28, 2025, 17:30 ET ARIS MINING ANNOUNCES POSITIVE PEA RESULTS FOR THE TOROPARU GOLD PROJECT
major technical study this year, following the Soto Norte Prefeasibility Study (PFS) in September, and together they demonstrate the strength of our growth pipeline beyond Segovia and Marmato. Aris Mining has initiated a PFS for Toroparu, targeted for completion in 2026, with the objective of advancing
More news about: Aris Mining Corporation
Oct 27, 2025, 14:23 ET YY Group公布2025年增長戰略：聚焦全球勞動力解決方案與IFM業務拓展
Circle今年已進駐3個新市場，目前海外業務約佔其用工總收入的45%。受益於內部數字營銷能力的增強，截至2025年6月30日，該平台新增企業客戶超80家，註冊勞動力規模較去年同期增加約12.2萬人。 IFM業務收購：2025年2月，YY Group收購了Property Facility Services Pte. Ltd.（「PFS」），為其設施管理服務整合策略奠定了基礎。隨後，該公司於2025年6月收購了Uniforce Security Pte. Ltd.和24IFM（原Managing Facilities Applications），並於2025年7月收購了Pesticide Pest Control Pte. Ltd.，大幅拓寬了其IFM服務組合和收入來源。
More news about: YY Group Holding Limited
Oct 27, 2025, 13:01 ET Three Cord True Wealth Management Unveils New Website for Better Client Communication
clarity at every step so successful families and business owners can make informed decisions with confidence," said Tod Arbutina, CPA, CFP®, MBA, CKA®, PFS. "The new site reflects our listen‑first, deeply customized approach and makes it easier to engage our team, access resources, and move from uncertainty
More news about: Three Cord True Wealth Management
Oct 27, 2025, 09:00 ET Financial Industry Veteran Sheryl Rowling Launches New Practice, Offering Highly Personalized Tax and Financial Planning for Individuals and Advisory Firms
Oct. 27, 2025 /PRNewswire/ -- Sheryl Rowling, a distinguished Certified Public Accountant (CPA) and Personal Financial Specialist (PFS), today announced the launch of her firm, Sheryl Rowling CPA Accountancy Corporation. The firm will provide a comprehensive suite of tax and financial
More news about: Sheryl Rowling CPA Accountancy Corporation
Oct 27, 2025, 08:30 ET YY Group Outlines 2025 Growth Strategy Featuring Global Workforce Solutions and IFM Expansion
2025. IFM Acquisitions: In February 2025, YY Group acquired Property Facility Services Pte. Ltd. ("PFS"), laying the groundwork for the Company's consolidated approach to facility management services. Since then, the Company has broadened its IFM service
More news about: YY Group Holding Limited
Oct 27, 2025, 07:15 ET ADC Therapeutics to Present at November Investor Conferences
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and
More news about: ADC Therapeutics SA
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
In addition, previously published data of external beam radiotherapy (EBRT) combined with osimertinib resulted in improved progression free survival (PFS) compared to osimertinib alone, providing a strong clinical rationale for combining targeted alpha-therapy via ATNM-400 with EGFR targeting therapies Sampath
More news about: Actinium Pharmaceuticals, Inc.
Oct 27, 2025, 06:00 ET West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
Key benefits of the West Synchrony PFS system include: Design and System-Level Performance: a single design verification and characterization package from West ensures the form, fit and function of the entire PFS system. Regulatory
More news about: West Pharmaceutical Services, Inc.
Oct 23, 2025, 18:54 ET Defense Metals Appoints Ali Mahdavi as SVP Corporate Development, and grants incentive stock options
the port facilities at Prince Rupert, the closest major North American port to Asia. The Company recently completed a Preliminary Feasibility Study (PFS) that demonstrated the robust economics of the project. For further information, please visit
More news about: Defense Metals Corp.
Oct 23, 2025, 17:00 ET ARIS MINING ANNOUNCES Q3 2025 EARNINGS RELEASE DATE
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Oct 23, 2025, 16:05 ET Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Ratio [HR] 0.479; 95% CI: 0.33, 0.68); P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic
More news about: Inhibrx Biosciences, Inc.
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
extramedullary disease and the patient with pPCL achieved sCR and remained in remission at last follow-up. The median progression-free survival (PFS) was 18.2 months, with 12-month PFS and overall survival (OS) rates of 82.1% and 93.3%, respectively. Safety: Cytokine
More news about: IASO Bio
Oct 21, 2025, 10:00 ET FP Alpha announces First-of-Its-Kind NextGen Tax Insights now available, assisting financial advisors in their tax planning advice to clients
"This level of AI-driven personalization is the 'wow factor' that's been missing from traditional tax planning," added Robert S. Keebler, CPA/PFS, MST, AEP, CGMA and partner with Keebler & Associates, LLP. "By moving beyond static insights to dynamic, scenario-based projections, FP
More news about: FP Alpha
Oct 21, 2025, 09:20 ET Gold Hits $4,300+ Creating Opportunity Across the Mining Sector
dilution to our capital structure," said Alan Carter, President and CEO of Cabral Gold Inc. "The financial metrics included within the recent PFS study make for a compelling opportunity, with a capex cost of US$37.7M, a post tax IRR of 78%, an NPV of US$74M and a payback of just 10 months, at a
More news about: USA News Group
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
KIT-driven tumors with translational biomarkers of target engagement (KIT knock-down, tryptase/MRK signaling) and early efficacy readouts (ORR, DCR, PFS signals). NEW YORK,
More news about: Hoth Therapeutics, Inc.
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 06:30 ET IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
safety and efficacy profile of darovasertib; (iii) the ongoing Phase 3 registrational trial (OptimUM-10) of darovasertib; (iv) the reporting of topline PFS data from the Phase2/3 (OptimUM-02) trial of darovasertib in combination with crizotinib by the end of 2025 to Q1'26; and (v) the potential U.S. accelerated
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 06:00 ET IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
months in published meta-analysis of metastatic uveal melanoma in the first-line setting Median progression free survival (PFS) of 7.0 months Confirmed overall response rate (ORR) by RECIST 1.1 of 34%, median duration of response (mDOR) of 9 months
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
platinum-based doublet chemotherapy, sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in both PFS and OS. Consistent PFS and OS benefits were observed across all prespecified subgroups, including prior EGFR-TKI therapy, presence of liver or brain metastases,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
expression (IHC 2+ >20%), the 2.4 mg/kg dose cohort observed 1 CR, 11 PRs and 15 SDs, resulting in 40% ORR (12/30) and 90% DCR (27/30). The median PFS was 6.97 months and the 12-month OS rate was 66.2%. In the 1.8 mg/kg dose cohort, there were 1 CR, 9 PRs, and 11 SDs, giving a 40% ORR (10/25)
More news about: Antengene Corporation Limited
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
the study are PFS and OS, and the secondary endpoints include objective response rate (ORR), disease control rate (DCR), and safety, etc. Results as of March 31, 2025, showed: Regarding PFS, the median PFS in the disitamab
More news about: RemeGen Co., Ltd
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
Median PFS was significantly longer in trastuzumab botidotin than in T-DM1 (11.1 months vs 4.4 months; HR: 0.39, 95% CI, 0.30-0.51, p<0.0001). PFS benefit with trastuzumab botidotin was consistently observed regardless of prior
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
date July 06, 2025, the median follow-up is 18.9 months. the median Progression-Free Survival (PFS) was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group. Sac-TMT significantly improved PFS over chemotherapy with 51% lower risk of disease progression or death (hazard ratio (HR) 0.49;
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
regimen. Among patients with liver metastases, the PFS HR was 0.53; among those without liver metastases, the PFS HR was 0.64. For patients with ≥3 baseline metastatic sites, the PFS HR was 0.46, and for those with <3 baseline metastatic sites, the PFS HR was 0.64.
More news about: Akeso, Inc.
Oct 19, 2025, 10:30 ET VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
86% (19 of 22 patients achieved a partial response or stable disease). Median Progression-Free Survival (PFS) of 40 weeks, which is more than double the 15-week benchmark for standard-of-care salvage chemotherapy. Study
More news about: Vivace Therapeutics, Inc.